HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety.

Authors :: Richardson, Paul G.
Oriol, Albert
Larocca, Alessandra
Otero, Paula Rodriguez
Norkin, Maxim
Bladé, Joan
Cavo, Michele
Hassoun, Hani
Leleu, Xavier
Alegre, Adrián
Maisel, Christopher
Paner, Agne
Mazumder, Amitabha
Zonder, Jeffrey A.
Puig, Noemí
Harran, John
Harmenberg, Johan
Thuresson, Sara
Zubair, Hanan
Mateos, Maria-Victoria
Source :: Clinical Lymphoma, Myeloma & Leukemia; 2019 Supplement 1, Vol. 19, pS329-S330, 2p
Publication Year :: 2019

Full Text Access

Tools